[
1. World Health Organization 2021 – Global Tuberculosis Report 2021 ISBN 978-92-4-003702-1 (electronic version). Available from: https://www.who.int/teams/global-tuberculosis-programme/tb-reports/global-tuberculosis-report-2021 [Accessed 10th November 2021].
]Search in Google Scholar
[
2. Cambau E, Drancourt M. Steps towards the discovery of Mycobacterium tuberculosis by Robert Koch, 1882. Clinical Microbiology and Infection. 2014;20(3): 196–201. Available from: doi:10.1111/1469-0691.12555.
]Open DOISearch in Google Scholar
[
3. Wrohan I, Nguyen TA, Nguyen VN, Nguyen BH, Hoang TTT, Nguyen PC, et al. Predictors of treatment outcomes among patients with multidrug-resistant tuberculosis in Vietnam: A retrospective cohort study. BMC Infectious Diseases. 2022;22(1): 68. Available from: doi:10.1186/s12879-021-06992-x.
]Open DOISearch in Google Scholar
[
4. Ong CWM, Goletti D. Impact of the global COVID-19 outbreak on the management of other communicable diseases. The International Journal Tuberculosis and Lung Disease. 2020;24(5): 547–548.10.5588/ijtld.20.0140
]Search in Google Scholar
[
5. Tiberi S, Vjecha MJ, Zumla A, Galvin J, Migliori GB, Zumla A, et al. Accelerating development of new shorter TB treatment regimens in anticipation of a resurgence of multi-drug resistant TB due to the COVID-19 pandemic. International Journal of Infectious Diseases. 2021;113(1): S96–S99. Available from: doi:10.1016/j.ijid.2021.02.067.
]Open DOISearch in Google Scholar
[
6. Katzung BG. Basic and clinical pharmacology, 14th Edition. United States of America: McGraw Hill Education, 2017.
]Search in Google Scholar
[
7. Egelund EF, Alsultan A, Peloquin CA. Optimizing the clinical pharmacology of tuberculosis medications. Clinical Pharmacology and Therapeutics. 2015;98(4): 387–393. Available from: doi:10.1002/cpt.180.
]Open DOISearch in Google Scholar
[
8. Ellard GA, Fourie PB. Rifampicin bioavailability: a review of its pharmacology and the chemotherapeutic necessity for ensuring optimal absorption. The International Journal of Tuberculosis and Lung Disease. 1999;3: S301–S308; discussion S317–S321.
]Search in Google Scholar
[
9. Bendre AD, Peters PJ, Kumar J. Tuberculosis: past, present, and future of the treatment and drug discovery research. Current Research in Pharmacology and Drug Discovery. 2021;2: 100037.10.1016/j.crphar.2021.100037
]Search in Google Scholar
[
10. WHO. Latent TB infection: Updated and consolidated guidelines for programmatic management. Geneva: World Health Organization; 2018 Available from: https://apps.who.int/iris/bitstream/handle/10665/260233/9789241550239-eng.pdf?sequence=1&isAllowed=y. [Accessed 10th November 2021].
]Search in Google Scholar
[
11. WHO. WHO operational handbook on tuberculosis. Module 4: Treatment – drug resistant tuberculosis treatment. Licence: CC BY-NC-SA 3.0 IGO. Geneva: World Health Organization; 2020 Available from: https://www.who.int/publications/i/item/9789240006997. WHO 2020. Consultation https://www.who.int/publications-detail-redirect/9789240006997 [Accessed 20th December 2021].
]Search in Google Scholar
[
12. Gülbay BE, Gürkan ÖU, Yıldız ÖA, Onen ZP, Erkekol FO, Baççioğlu A, et al. Side effects due to primary antituberculosis drugs during the initial phase of therapy in 1149 hospitalized patients for tuberculosis. Respiratory Medicine. 2006;100(10): 1834–1842.10.1016/j.rmed.2006.01.014
]Search in Google Scholar
[
13. Lan Z, Ahmad N, Baghaei P, Barkane L, Benedetti A, Brode SK, et al. Drug-associated adverse events in the treatment of multidrug-resistant tuberculosis: an individual patient data meta-analysis. The Lancet Respiratory Medicine. 2020;8(4): 383–394. Available from: doi:10.1016/S2213-2600(20)30047-3.
]Open DOISearch in Google Scholar
[
14. Sun W, Wu Z, Zhou Y, et al. A highly effective and inexpensive standardized treatment of multidrug-resistant tuberculosis: a multicenter prospective study in China. BMC Infect Dis. 2021;21(1): 834. Available from: https://doi.org/10.1186/s12879-021-06553-2.10.1186/s12879-021-06553-2837440834412615
]Search in Google Scholar
[
15. Conradie F, Diacon AH, Ngubane N, Howell P, Everitt D, Crook AM, et al. Treatment of highly drug-resistant pulmonary tuberculosis. The New England Journal Medicine. 2020;382(10): 893–902. Available from: doi:10.1056/NEJMoa1901814.695564032130813
]Open DOISearch in Google Scholar
[
16. World Health Organization. WHO Consolidated Guidelines on Drug-Resistant Tuberculosis Treatment. Geneva: WHO; 2019 (WHO/CDS/TB/2019.7) Available from: https://apps.who.int/iris/bitstream/handle/10665/311389/9789241550529-eng.pdf [ Accessed 18th December 2021].
]Search in Google Scholar
[
17. Lièvre M, Cucherat M, Leizorovicz A. Pooling, meta-analysis, and the evaluation of drug safety. Current Controlled Trials in Cardiovascular Medicine. 2002;3(1): 6. Available from: doi:10.1186/1468-6708-3-6.13447811991807
]Open DOISearch in Google Scholar
[
18. Palma-Alvarez RF, Duque-Yemail J, Ros-Cucurull E, Robles-Martínez M, Perea-Ortueta M, Grau-López L, et al. Quinolone-induced psychosis: An updated review. Actas Españolas de Psiquiatría. 2020;48(3): 126–137.
]Search in Google Scholar
[
19. Shehab N, Patel PR, Srinivasan A, Budnitz DS. Emergency department visits for antibiotic-associated adverse events. Clinical Infectious Diseases. 2008;47(6): 735–743.10.1086/59112618694344
]Search in Google Scholar
[
20. Stahlmann R, Lode HM. Risks associated with the therapeutic use of fluoroquinolones. Expert Opinion on Drug Safety. 2013;12(4): 497–505. Available from: doi:10.1517/14740338.2013.796362.23651367
]Open DOISearch in Google Scholar
[
21. Sheffield ME, Jones BM, Terrell B, Wagner JL, Bland CM. Influence of probiotics on the development of Clostridioides difficile infection in patients receiving fluoroquinolones. Pharmacy (Basel). 2021;9(3): 141. Available from: doi:10.3390/pharmacy9030141.839616834449745
]Open DOISearch in Google Scholar
[
22. Arbex MA, de Castro Lima Varella M, de Siqueira HB, de Mello FAF. Antituberculosis drugs: drug interactions, adverse effects, and use in special situations. Part 2: second-line drugs. Jornal Brasileiro de Pneumologia. 2010;36(5): 641–656.10.1590/S1806-37132010000500017
]Search in Google Scholar
[
23. Chide OE, Orisakwe OE. Structural development, haematological immunological and pharmacological effects of quinolones. Recent Patents on Anti-Infective Drug Discovery. 2007;2: 157–168.10.2174/15748910778083266818221172
]Search in Google Scholar
[
24. Ausi Y, Santoso P, Sunjaya DK, Barliana MI. Between curing and torturing: Burden of adverse reaction in drug-resistant tuberculosis therapy. Patient Preference and Adherence. 2021;15: 2597–2607. Available form: doi:10.2147/ppa.s333111.
]Open DOISearch in Google Scholar
[
25. Rubinstein E. History of quinolones and their side effects. Chemotherapy 2001;47(3): 3–8.10.1159/00005783811549783
]Search in Google Scholar
[
26. Minardi ML, Fato I, Di Gennaro F, Mosti S, Mastrobattista A, Cerva C, et al. Common and rare hematological manifestations and adverse drug events during treatment of active TB: A state of art. Microorganisms. 2021;9(7): 1477. Available from: doi:10.3390/microorganisms9071477.830468034361913
]Open DOISearch in Google Scholar
[
27. Borisov SE, Dheda K, Enwerem M, Romero Leyet R, D’Ambrosio L, Centis R, et al. Effectiveness and safety of bedaquiline-containing regimens in the treatment of MDR – and XDR-TB: a multicentre study. The European Respiratory Journal. 2017;49(5): 1700387. Available from: doi:10.1183/13993003.00387-2017.28529205
]Open DOISearch in Google Scholar
[
28. Guglielmetti L, Barkane L, Le Dû D, Marigot-Outtandy D, Robert J, Veziris N, et al. Safety and efficacy of exposure to bedaquilinedelamanid in multidrug-resistant tuberculosis: a case series from France and Latvia. The European Respiratory Journal. 2018;51: 1702550.10.1183/13993003.02550-2017
]Search in Google Scholar
[
29. Jang JG, Chung JH. Diagnosis and treatment of multidrug-resistant tuberculosis. Yeungnam University Journal of Medicine. 2020;37(4): 277–285. Available from: doi:10.12701/yujm.2020.00626.
]Open DOISearch in Google Scholar
[
30. de Jager P, van Altena R. Hearing loss and nephrotoxicity in long-term aminoglycoside treatment in patients with tuberculosis. The International Journal of Tuberculosis and Lung Disease. 2002;6(7): 622–627.
]Search in Google Scholar
[
31. Gupta A, Kumar V, Natarajan S, Singla R. Adverse drug reactions & drug interactions in MDR-TB patients. The Indian Journal of Tuberculosis. 2020;67(4S): S69–S78. Available from: doi:10.1016/j.ijtb.2020.09.027.
]Open DOISearch in Google Scholar
[
32. Gopal P, Grüber G, Dartois V, Dick T. Pharmacological and molecular mechanisms behind the sterilizing activity of pyrazinamide. Trends in Pharmacological Sciences. 2019;40(12): 930–940. Available from: doi:10.1016/j.tips.2019.10.005.
]Open DOISearch in Google Scholar
[
33. Sood D, Kumar N, Singh A, Sakharkar MK, Tomar V, Chandra R, et al. Antibacterial and pharmacological evaluation of fluoroquinolones: a chemoinformatics approach. Genomics and Informatics. 2018;16(3): 44–51.10.5808/GI.2018.16.3.44
]Search in Google Scholar
[
34. Rizzi MD, Hirose K. Aminoglycoside ototoxicity. Current Opinion in Otolaryngology & Head and Neck Surgery. 2007;15: 352–357.10.1097/MOO.0b013e3282ef772d
]Search in Google Scholar
[
35. Li Y, Wang F, Wu L, Zhu M, He G, Chen X, et al. Cycloserine for treatment of multidrug-resistant tuberculosis: a retrospective cohort study in China. Infection and Drug Resistance. 2019;12: 721–731.10.2147/IDR.S195555
]Search in Google Scholar
[
36. Seaworth BJ. Multidrug-resistant tuberculosis. Infectious Disease Clinics of North America. 2002;16(1):73–105.10.1016/S0891-5520(03)00047-3
]Search in Google Scholar
[
37. Blumberg HM, Burman WJ, Chaisson RE, Daley CL, Etkind SC, Friedman LN, et al. American thoracic society/centers for disease control and prevention/Infectious diseases society of America: treatment of tuberculosis. American Journal of Respiratory and Critical Care Medicine. 2003;167(4): 603–662.10.1164/rccm.167.4.60312588714
]Search in Google Scholar
[
38. Peloquin CA, Berning SE, Nitta AT, Simone PM, Goble M, Huitt GA, et al. Aminoglycoside toxicity: daily versus thrice-weekly dosing for treatment of mycobacterial diseases. Clinical Infectious Diseases. 2004;38(11): 1538–1544.10.1086/42074215156439
]Search in Google Scholar
[
39. Guthrie OW. Aminoglycoside induced ototoxicity. Toxicology. 2008;249(2–3): 91–96.10.1016/j.tox.2008.04.01518514377
]Search in Google Scholar
[
40. Wargo AK, Edwards JD. Aminoglycoside-induced nephrotoxicity. Journal of Pharmacy Practice. 2014;27(6): 573–577.10.1177/089719001454683625199523
]Search in Google Scholar
[
41. Rougier F, Claude D, Maurin M, Sedoglavic A, Ducher M, Corvaisier S, et al. Aminoglycoside nephrotoxicity: Modeling, simulation, and control. Antimicrobial Agents and Chemotherapy. 2003;47(3): 1010–1016.10.1128/AAC.47.3.1010-1016.2003
]Search in Google Scholar
[
42. Jain AK, Sharma P. Ethionamide induced blue vision (cyanopsia): case report. Indian Journal of Tuberculosis. 2020;67(3): 333–335.10.1016/j.ijtb.2019.04.011
]Search in Google Scholar
[
43. Gumbo T. Chemotherapy of tuberculosis, Mycobacterium avium complex disease, and leprosy. In: Brunton LL, Chabner BA, Knollmann BC. (eds.) Goodman & Gilman’s the pharmacological basis of therapeutics, 12th ed. New Delhi: McGraw Hill; 2011. p.1549–1570.
]Search in Google Scholar
[
44. Zhang Y. The magic bullets and tuberculosis drug targets. Annual Review of Pharmacology and Toxicology. 2005;45: 529–564.10.1146/annurev.pharmtox.45.120403.100120
]Search in Google Scholar
[
45. Abulfathi AA, Donald PR, Adams K, Svensson EM, Diacon A, Reuter H, et al. The pharmacokinetics of para-aminosalicylic acid and its relationship to efficacy and intolerance. British Journal Clinical Pharmacology. 2020;86: 2123–2132. Available form: doi:10.1111/bcp.14395.
]Open DOISearch in Google Scholar
[
46. Lehmann J. Para-aminosalicylic acid in the treatment of tuberculosis. The Lancet. 1946;247(6384): 15–16.10.1016/S0140-6736(46)91185-3
]Search in Google Scholar
[
47. Weng T, Sun F, Li Y, Chen J, Chen X, Li R, et al. Refining MDRTB treatment regimens for ultra short therapy (TB-TRUST): study protocol for a randomized controlled trial. BMC Infectious Diseases. 2021;21(1): 183. Available form: doi:10.1186/s12879-021-05870-w.788813733596848
]Open DOISearch in Google Scholar
